3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
3
Neoplasm Metastasis
2
Breast Neoplasms
2
Sarcoma, Synovial
1
Sarcoma
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
Dermatofibrosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Doxorubicin
6
Trabectedin
5
pazopanib
4
Radiotherapy
4
ribociclib
3
pembrolizumab
3
palbociclib
3
Gemcitabine
3
brostallicin
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Immunoglobulin G
2
Imatinib Mesylate
2
Ifosfamide
2
Docetaxel
2
Dexamethasone
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
tanespimycin
1
talimogene laherparepvec
1
sotigalimab
1
soblidotin
1
sitravatinib
1
saracatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liposarcoma
×
Quality of Life
×
Clear all
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled